In vivo gene therapy of type I diabetic mellitus using a cationic emulsion containing an Epstein Barr Virus (EBV) based plasmid vector

Hyuk Sang Yoo; Osam Mazda; Hyeon Yong Lee; Jin Chul Kim; Seok Min Kwon; Jung Eun Lee; Ick Chan Kwon; Hesson Jeong; Yu Seok Jeong; Seo Young Jeong

doi:10.1016/j.jconrel.2006.01.019

In vivo gene therapy of type I diabetic mellitus using a cationic emulsion containing an Epstein Barr Virus (EBV) based plasmid vector

Hyuk Sang Yoo, Osam Mazda, Hyeon Yong Lee, Jin Chul Kim, Seok Min Kwon, Jung Eun Lee, Ick Chan Kwon, Hesson Jeong, Yu Seok Jeong, Seo Young Jeong

KU-KIST Graduate School of Converging Science and Technology

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

A cationic emulsion containing an insulin expression plasmid was prepared for the treatment of type 1 diabetic mellitus (DM) in vivo. A rat proinsulin-1 gene was inserted to EBV-based plasmid vectors containing CAG promoter. Cationic emulsion composed of DOTAP and squalene was complexed with the plasmid DNA. An intravenous injection of cationic emulsion containing proinsulin gene decreased blood glucose levels for 7 days within normal range. The cationic emulsion exerted more profound effect on blood glucose levels compared to naked DNA. RT-PCR results confirmed that the proinsulin was expressed in several organs containing liver, lung, spleen, and kidney. The refractory response was invoked by multiple injections of naked DNA or cationic emulsion/DNA complex, which was later proven to be an immune response against expressed proinsulin. Therefore, the cationic emulsion showed a promising result as a novel insulin gene therapy vehicle by decreasing blood glucose level for a month.

Original language	English
Pages (from-to)	139-144
Number of pages	6
Journal	Journal of Controlled Release
Volume	112
Issue number	1
DOIs	https://doi.org/10.1016/j.jconrel.2006.01.019
Publication status	Published - 2006 May 1

Keywords

Cationic emulsion
Diabetic
Gene therapy
Insulin

ASJC Scopus subject areas

Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jconrel.2006.01.019

Cite this

@article{b43e4a6aef2048f9a69b69f5ab8ea916,

title = "In vivo gene therapy of type I diabetic mellitus using a cationic emulsion containing an Epstein Barr Virus (EBV) based plasmid vector",

abstract = "A cationic emulsion containing an insulin expression plasmid was prepared for the treatment of type 1 diabetic mellitus (DM) in vivo. A rat proinsulin-1 gene was inserted to EBV-based plasmid vectors containing CAG promoter. Cationic emulsion composed of DOTAP and squalene was complexed with the plasmid DNA. An intravenous injection of cationic emulsion containing proinsulin gene decreased blood glucose levels for 7 days within normal range. The cationic emulsion exerted more profound effect on blood glucose levels compared to naked DNA. RT-PCR results confirmed that the proinsulin was expressed in several organs containing liver, lung, spleen, and kidney. The refractory response was invoked by multiple injections of naked DNA or cationic emulsion/DNA complex, which was later proven to be an immune response against expressed proinsulin. Therefore, the cationic emulsion showed a promising result as a novel insulin gene therapy vehicle by decreasing blood glucose level for a month.",

keywords = "Cationic emulsion, Diabetic, Gene therapy, Insulin",

author = "Yoo, {Hyuk Sang} and Osam Mazda and Lee, {Hyeon Yong} and Kim, {Jin Chul} and Kwon, {Seok Min} and Lee, {Jung Eun} and Kwon, {Ick Chan} and Hesson Jeong and Jeong, {Yu Seok} and Jeong, {Seo Young}",

note = "Funding Information: This work was supported by grant No. RTI05-01-02 from the Regional Technology Innovation Program of the Ministry of Commerce, Industry and Energy (MOCIE). Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2006",

month = may,

day = "1",

doi = "10.1016/j.jconrel.2006.01.019",

language = "English",

volume = "112",

pages = "139--144",

journal = "Journal of Controlled Release",

issn = "0168-3659",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - In vivo gene therapy of type I diabetic mellitus using a cationic emulsion containing an Epstein Barr Virus (EBV) based plasmid vector

AU - Yoo, Hyuk Sang

AU - Mazda, Osam

AU - Lee, Hyeon Yong

AU - Kim, Jin Chul

AU - Kwon, Seok Min

AU - Lee, Jung Eun

AU - Kwon, Ick Chan

AU - Jeong, Hesson

AU - Jeong, Yu Seok

AU - Jeong, Seo Young

N1 - Funding Information: This work was supported by grant No. RTI05-01-02 from the Regional Technology Innovation Program of the Ministry of Commerce, Industry and Energy (MOCIE). Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2006/5/1

Y1 - 2006/5/1

N2 - A cationic emulsion containing an insulin expression plasmid was prepared for the treatment of type 1 diabetic mellitus (DM) in vivo. A rat proinsulin-1 gene was inserted to EBV-based plasmid vectors containing CAG promoter. Cationic emulsion composed of DOTAP and squalene was complexed with the plasmid DNA. An intravenous injection of cationic emulsion containing proinsulin gene decreased blood glucose levels for 7 days within normal range. The cationic emulsion exerted more profound effect on blood glucose levels compared to naked DNA. RT-PCR results confirmed that the proinsulin was expressed in several organs containing liver, lung, spleen, and kidney. The refractory response was invoked by multiple injections of naked DNA or cationic emulsion/DNA complex, which was later proven to be an immune response against expressed proinsulin. Therefore, the cationic emulsion showed a promising result as a novel insulin gene therapy vehicle by decreasing blood glucose level for a month.

AB - A cationic emulsion containing an insulin expression plasmid was prepared for the treatment of type 1 diabetic mellitus (DM) in vivo. A rat proinsulin-1 gene was inserted to EBV-based plasmid vectors containing CAG promoter. Cationic emulsion composed of DOTAP and squalene was complexed with the plasmid DNA. An intravenous injection of cationic emulsion containing proinsulin gene decreased blood glucose levels for 7 days within normal range. The cationic emulsion exerted more profound effect on blood glucose levels compared to naked DNA. RT-PCR results confirmed that the proinsulin was expressed in several organs containing liver, lung, spleen, and kidney. The refractory response was invoked by multiple injections of naked DNA or cationic emulsion/DNA complex, which was later proven to be an immune response against expressed proinsulin. Therefore, the cationic emulsion showed a promising result as a novel insulin gene therapy vehicle by decreasing blood glucose level for a month.

KW - Cationic emulsion

KW - Diabetic

KW - Gene therapy

KW - Insulin

UR - http://www.scopus.com/inward/record.url?scp=33645753059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645753059&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2006.01.019

DO - 10.1016/j.jconrel.2006.01.019

M3 - Article

C2 - 16530875

AN - SCOPUS:33645753059

SN - 0168-3659

VL - 112

SP - 139

EP - 144

JO - Journal of Controlled Release

JF - Journal of Controlled Release

IS - 1

ER -

In vivo gene therapy of type I diabetic mellitus using a cationic emulsion containing an Epstein Barr Virus (EBV) based plasmid vector

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this